References to Primary Literature
- KOCH AE, KUNKEL SL, STREETER RM: Cytokines in rheu-matoid arthritis. J. Invest. Med. (1995) 43(1):28–38.
- KOCH K, BURGESS LE: Anti-inflammatory patent high-lights January - July 1994. Exp. Opin. Ther. Patents (1995) 5(2):127–156.
- PENNING TD, FRETLAND DJ, STEALEY MA: Anti-inflam-matory patent highlights from July 1994 to Apri11995. Exp. Opin. Ther. Patents (1999 5(7):623–641.
- Synergen considering 'strategic alternatives' after An-tal sepsis failure. FDC Reports Pink Sheets (1994)
- Bradycor disappoints in sepsis. SCRIP (1994) 1944:23.
- PUGH MT, GILLOT T: A double blind study assessing the efficacy of a novel IL-1 antagonist, IX207-887 for the treatment of rheumatoid arthritis. Arthritis Rheum. (1995) 38(9):Abs.780.
- YOSHIHARA R, SHIOZAWA S: Cytokine and anti-cytokine therapy. Igaku No Ayumi (1994) 169(2).135–139
- Pipeline news: focus on Sanofi. R&D Focus Dnig News (1994) 3(47).4–5
- SANOFI Information meeting. Sanofi Company Brochure (1995) Spring.
- SUGITA T, UENO M, FURUICAWA 0, MURAKAMI T, TAKATA J, TOSA T: Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis-suppressive effect of TA-383 on interleukin-6 production. Int. J. Immuno-pharrn. (1993) 15(4):515–519.